Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 26, 2016 - Issue 2
Submit an article Journal homepage
312
Views
7
CrossRef citations to date
0
Altmetric
Reviews

The triumph of chemically enhanced cellular reprogramming: a patent review

Muhammad Ayaz AnwarDepartment of Molecular Science and Technology, Ajou University, Suwon, South Korea
,
Songmee KimDepartment of Molecular Science and Technology, Ajou University, Suwon, South Korea
&
Sangdun ChoiDepartment of Molecular Science and Technology, Ajou University, Suwon, South KoreaCorrespondence[email protected]
Pages 265-280 | Received 27 Jun 2015, Accepted 05 Nov 2015, Published online: 04 Dec 2015

References

  • Reference annotations
  • * Of interest
  • ** Of considerable interest
  • Hu K, Slukvin I. Generation of transgene-free iPSC lines from human normal and neoplastic blood cells using episomal vectors. Methods Mol Biol. 2013;997:163–176.
  • Hou P, Li Y, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science. 2013;341:651–654.
  • Kaji K, Norrby K, Paca A, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature. 2009;458:771–775.
  • Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science. 2009;324:797–801.
  • Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4:472–476.
  • Ban H, Nishishita N, Fusaki N, et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci U S A. 2011;108:14234–14239.
  • Zhou YY, Zeng F. Integration-free methods for generating induced pluripotent stem cells. Genomics Proteomics Bioinform. 2013;11:284–287.

** An excellent review of non-integral methods for stem cell generation.

  • Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917–1920.
  • Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676.
  • Feng B, Jiang J, Kraus P, et al. Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb. Nat Cell Biol. 2009;11:197–203.
  • Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009;4:381–384.
  • Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration. Science. 2008;322:945–949.
  • Okita K, Nakagawa M, Hyenjong H, et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science. 2008;322:949–953.
  • French AJ, Adams CA, Anderson LS, et al. Development of human cloned blastocysts following somatic cell nuclear transfer with adult fibroblasts. Stem Cells. 2008;26:485–493.
  • Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–872.
  • Huangfu D, Maehr R, Guo W, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol. 2008;26:795–797.
  • Liang G, Taranova O, Xia K, et al. Butyrate promotes induced pluripotent stem cell generation. J Biol Chem. 2010;285:25516–25521.
  • Bar-Nur O, Brumbaugh J, Verheul C, et al. Small molecules facilitate rapid and synchronous iPSC generation. Nat Methods. 2014;11:1170–1176.

* Comprehensively reports the importance of small molecules in biology.

  • Shi Y, Desponts C, Do JT, et al. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell. 2008;3:568–574.
  • Tachibana M, Amato P, Sparman M, et al. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell. 2013;153:1228–1238.
  • Higuchi A, Ling QD, Kumar SS, et al. Generation of pluripotent stem cells without the use of genetic material. Lab Invest. 2015;95:26–42.
  • Zhu S, Li W, Zhou H, et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell. 2010;7:651–655.
  • Hemberger M, Dean W, Reik W. Epigenetic dynamics of stem cells and cell lineage commitment: digging Waddington’s canal. Nat Rev Mol Cell Biol. 2009;10:526–537.
  • Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell. 2007;128:635–638.

** A concise report regarding various features of epigenetics.

  • Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet. 2013;14:204–220.
  • Mikkelsen TS, Hanna J, Zhang X, et al. Dissecting direct reprogramming through integrative genomic analysis. Nature. 2008;454:49–55.
  • Pawlak M, Jaenisch R. De novo DNA methylation by Dnmt3a and Dnmt3b is dispensable for nuclear reprogramming of somatic cells to a pluripotent state. Genes Dev. 2011;25:1035–1040.
  • Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693–705.
  • Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10:32–42.
  • Pandian GN, Nakano Y, Sato S, et al. A synthetic small molecule for rapid induction of multiple pluripotency genes in mouse embryonic fibroblasts. Sci Rep. 2012;2:544.
  • Pandian GN, Shinohara K, Ohtsuki A, et al. Synthetic small molecules for epigenetic activation of pluripotency genes in mouse embryonic fibroblasts. ChemBioChem. 2011;12:2822–2828.
  • Pandian GN, Sato S, Anandhakumar C, et al. Identification of a small molecule that turns ON the pluripotency gene circuitry in human fibroblasts. ACS Chem Biol. 2014;9:2729–2736.
  • Mali P, Chou BK, Yen J, et al. Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells. 2010;28:713–720.
  • Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010;6:238–243.
  • Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol. 2008;26:1269–1275.
  • Itoh Y, Suzuki T, Miyata N. Isoform-selective histone deacetylase inhibitors. Curr Pharm Des. 2008;14:529–544.
  • Onder TT, Kara N, Cherry A, et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature. 2012;483:598–602.
  • Nguyen AT, Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev. 2011;25:1345–1358.
  • Chen J, Liu H, Liu J, et al. H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat Genet. 2013;45:34–42.
  • Schotta G, Ebert A, Krauss V, et al. Central role of Drosophila SU(VAR)3-9 in histone H3-K9 methylation and heterochromatic gene silencing. Embo J. 2002;21:1121–1131.
  • Kubicek S, O’Sullivan RJ, August EM, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007;25:473–481.
  • Liu F, Wu P, Liu K Verticillin A Inhibition of Histone Methyltransferases. US20140161785. 2014.
  • Yuan Y, Wang Q, Paulk J, et al. A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem Biol. 2012;7:1152–1157.
  • Vedadi M, Barsyte-Lovejoy D, Liu F, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol. 2011;7:566–574.
  • Chang Y, Zhang X, Horton JR, et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol. 2009;16:312–317.
  • Liu F, Chen X, Allali-Hassani A, et al. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J Med Chem. 2009;52:7950–7953.
  • Yuan X, Wan H, Zhao X, et al. Brief report: combined chemical treatment enables Oct4-induced reprogramming from mouse embryonic fibroblasts. Stem Cells. 2011;29:549–553.
  • Li W, Zhou H, Abujarour R, et al. Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells. 2009;27:2992–3000.
  • Cheng D, Yadav N, King RW, et al. Small molecule regulators of protein arginine methyltransferases. J Biol Chem. 2004;279:23892–23899.
  • Kingston WR. A clinical trial of an antidepressant, tranylcy-promine (“Parnate”). Med J Aust. 1962;49:1011–1012.
  • Esteban MA, Wang T, Qin B, et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell. 2010;6:71–79.
  • Blaschke K, Ebata KT, Karimi MM, et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature. 2013;500:222–226.
  • McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492:108–112.
  • Koche RP, Smith ZD, Adli M, et al. Reprogramming factor expression initiates widespread targeted chromatin remodeling. Cell Stem Cell. 2011;8:96–105.
  • Fragola G, Germain PL, Laise P, et al. Cell reprogramming requires silencing of a core subset of polycomb targets. PLoS Genet. 2013;9:e1003292.
  • Mansour AA, Gafni O, Weinberger L, et al. The H3K27 demethylase Utx regulates somatic and germ cell epigenetic reprogramming. Nature. 2012;488:409–413.
  • Rao RA, Dhele N, Cheemadan S, et al. Ezh2 mediated H3K27me3 activity facilitates somatic transition during human pluripotent reprogramming. Sci Rep. 2015;5:8229.
  • Lee J, Xia Y, Son MY, et al. A novel small molecule facilitates the reprogramming of human somatic cells into a pluripotent state and supports the maintenance of an undifferentiated state of human pluripotent stem cells. Angew Chem Int Ed Engl. 2012;51:12509–12513.
  • Li W, Tian E, Chen ZX, et al. Identification of Oct4-activating compounds that enhance reprogramming efficiency. Proc Natl Acad Sci U S A. 2012;109:20853–20858.
  • Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9:28–39.
  • Zebisch A, Czernilofsky AP, Keri G, et al. Signaling through RAS-RAF-MEK-ERK: from basics to bedside. Curr Med Chem. 2007;14:601–623.
  • Silva J, Barrandon O, Nichols J, et al. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol. 2008;6:e253.
  • Chen S, Do JT, Zhang Q, et al. Self-renewal of embryonic stem cells by a small molecule. Proc Natl Acad Sci U S A. 2006;103:17266–17271.
  • Claassen DA, Desler MM, Rizzino A. ROCK inhibition enhances the recovery and growth of cryopreserved human embryonic stem cells and human induced pluripotent stem cells. Mol Reprod Dev. 2009;76:722–732.
  • Xu Y, Zhu X, Hahm HS, et al. Revealing a core signaling regulatory mechanism for pluripotent stem cell survival and self-renewal by small molecules. Proc Natl Acad Sci U S A. 2010;107:8129–8134.
  • Staerk J, Lyssiotis CA, Medeiro LA, et al. Pan-Src family kinase inhibitors replace Sox2 during the direct reprogramming of somatic cells. Angew Chem Int Ed Engl. 2011;50:5734–5736.
  • Li Z, Rana TM. A kinase inhibitor screen identifies small-molecule enhancers of reprogramming and iPS cell generation. Nat Commun. 2012;3:1085.
  • Wu D, Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci. 2010;35:161–168.
  • Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov. 2004;3:479–487.
  • Lyssiotis CA, Foreman RK, Staerk J, et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U S A. 2009;106:8912–8917.
  • Ten Berge D, Kurek D, Blauwkamp T, et al. Embryonic stem cells require Wnt proteins to prevent differentiation to epiblast stem cells. Nat Cell Biol. 2011;13:1070–1075.
  • Marson A, Foreman R, Chevalier B, et al. Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell. 2008;3:132–135.
  • Holland JD, Klaus A, Garratt AN, et al. Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol. 2013;25:254–264.
  • Ho R, Papp B, Hoffman JA, et al. Stage-specific regulation of reprogramming to induced pluripotent stem cells by Wnt signaling and T cell factor proteins. Cell Rep. 2013;3:2113–2126.
  • Muralidharan S, Hanley PJ, Liu E, et al. Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes. J Immunol. 2011;187:5221–5232.
  • Takada R, Satomi Y, Kurata T, et al. Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. Dev Cell. 2006;11:791–801.
  • Chen B, Dodge ME, Tang W, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 2009;5:100–107.
  • Kirby LA, Schott JT, Noble BL, et al. Glycogen synthase kinase 3 (GSK3) inhibitor, SB-216763, promotes pluripotency in mouse embryonic stem cells. PLoS One. 2012;7:e39329.
  • Meijer L, Skaltsounis AL, Magiatis P, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol. 2003;10:1255–1266.
  • Sato N, Meijer L, Skaltsounis L, et al. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med. 2004;10:55–63.
  • Ding S, Wu TY, Brinker A, et al. Synthetic small molecules that control stem cell fate. Proc Natl Acad Sci U S A. 2003;100:7632–7637.
  • Varga AC, Wrana JL. The disparate role of BMP in stem cell biology. Oncogene. 2005;24:5713–5721.
  • Li R, Liang J, Ni S, et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell. 2010;7:51–63.
  • Ichida JK, Blanchard J, Lam K, et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell. 2009;5:491–503.
  • Maherali N, Hochedlinger K. Tgfbeta signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc. Curr Biol. 2009;19:1718–1723.
  • Inman GJ, Nicolas FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62:65–74.
  • Lin T, Ambasudhan R, Yuan X, et al. A chemical platform for improved induction of human iPSCs. Nat Methods. 2009;6:805–808.
  • Peng SB, Yan L, Xia X, et al. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry. 2005;44:2293–2304.
  • Kimura T, Kaga Y, Sekita Y, et al. Pluripotent stem cells derived from mouse primordial germ cells by small molecule compounds. Stem Cells. 2015;33:45–55.
  • Samavarchi-Tehrani P, Golipour A, David L, et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell. 2010;7:64–77.
  • Miyabayashi T, Yamamoto M, Sato A, et al. Indole derivatives sustain embryonic stem cell self-renewal in long-term culture. Biosci Biotechnol Biochem. 2008;72:1242–1248.
  • Hasegawa K, Yasuda SY, Teo JL, et al. Wnt signaling orchestration with a small molecule DYRK inhibitor provides long-term xeno-free human pluripotent cell expansion. Stem Cells Transl Med. 2012;1:18–28.
  • Ichida JK, Tcw J, Williams LA, et al. Notch inhibition allows oncogene-independent generation of iPS cells. Nat Chem Biol. 2014;10:632–639.
  • Liu Y, Li P, Liu K, et al. Timely inhibition of Notch signaling by DAPT promotes cardiac differentiation of murine pluripotent stem cells. PLoS One. 2014;9:e109588.
  • Wang W, Yang J, Liu H, et al. Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor gamma and liver receptor homolog 1. Proc Natl Acad Sci U S A. 2011;108:18283–18288.
  • Yoshida Y, Takahashi K, Okita K, et al. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell. 2009;5:237–241.
  • Panopoulos AD, Yanes O, Ruiz S, et al. The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res. 2012;22:168–177.
  • Shi Y, Do JT, Desponts C, et al. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell. 2008;2:525–528.
  • Shi Y, Zou M, Baitei EY, et al. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. Cancer Gene Ther. 2008;15:101–107.
  • Moon JH, Heo JS, Kim JS, et al. Reprogramming fibroblasts into induced pluripotent stem cells with Bmi1. Cell Res. 2011;21:1305–1315.
  • Chen T, Shen L, Yu J, et al. Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell. 2011;10:908–911.
  • Ying QL, Wray J, Nichols J, et al. The ground state of embryonic stem cell self-renewal. Nature. 2008;453:519–523.
  • Li Y, Zhang Q, Yin X, et al. Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules. Cell Res. 2011;21:196–204.
  • Insel PA, Ostrom RS. Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. Cell Mol Neurobiol. 2003;23:305–314.
  • Chiang PK. Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. Pharmacol Ther. 1998;77:115–134.
  • Gordon RK, Ginalski K, Rudnicki WR, et al. Anti-HIV-1 activity of 3-deaza-adenosine analogs. Inhibition of S-adenosylhomocysteine hydrolase and nucleotide congeners. Eur J Biochem. 2003;270:3507–3517.
  • Cooney M, Czernuszewicz G, Postel EH, et al. Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science. 1988;241:456–459.
  • Jain A, Wang G, Vasquez KM. DNA triple helices: biological consequences and therapeutic potential. Biochimie. 2008;90:1117–1130.
  • Morrisey EE MicroRNA induction of pluripotential stem cells and uses thereof. US20130035374A1. 2013.
  • Saha K, Mei Y, Bogatyrev SR, et al. Substrates and methods for culturing stem cells. US 20100273259A1. 2010.
  • Hill BL, Lavau CP, Young JC Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors. WO2000023567A2. 2000.
  • Jang YY, Sharkis SJ Compositions and methods for somatic tissue induced pluripotent stem cells having an endoderm origin. WO2011084747A2. 2011.
  • Hai Z, Yu Z, Jia T, et al. Culture solution for promoting in-vitro growth of porcine somatic cell cloned embryos. CN103952368A. 2014.
  • Song Y, Chen P, Diao J, et al. Selective inhibitors of histone methyltransferase dot1l. US20140100184A1. 2014.
  • Shi Y, Lan F Histone demethylation proteins and methods of use thereof. WO2009114011A1. 2009.
  • Kuntz KW, Huang KC, Choi HW, et al. Salt form of a human hi stone methyltransf erase ezh2 inhibitor. WO2013155317A1. 2013.
  • Shi Y, Desponts C, Ding S Combined chemical and genetic approaches for generation of induced pluripotent stem cells. WO2009117439A2. 2009.
  • Liu F, Wu P, Liu K Verticillin A Inhibition of Histone Methyltransferases. US20140161785A1. 2014.
  • Deng-Hong K, Zhang Y, Hou P, et al. Method, kit and applications of preparing pluripotent stem cells through small-molecule compound treatment. WO2015003643A1. 2015.
  • Shi Y, Yip ML, Li W Enhancers of induced pluripotent stem cell reprogramming. US20140154805A1. 2014.
  • Li W, Lin T, Ding S Improved methods of generating pluripotent stem cells. WO2011109015A1. 2011.
  • Pei D, Chen J, Liu J Additif pour milieu de culture et ses utilisations. WO2011134210A1. 2011.
  • Kahn M, Hasegawa K, Teo JL, et al. Method for formation of induced pluripotent stem cells. WO2011019957A1. 2011.
  • Eilertsen KJ, Power RA Reprogramming a Cell by Inducing a Pluripotent Gene Through Use of a Small Molecule Modulator. US20090253203A1. 2009.
  • Cho YS, Lee K, Lee JW Novel low-molecule compound for promoting pluripotent stem cell generation, maintenance, and proliferation, and composition and culturing method containing same. WO2013180350A1. 2013.
  • Mrowka R, Wolf G, Wolfl S, et al. Method for activating oct4 for induction of pluripotent stem cells. WO2014000814A1. 2014.
  • Hidenori A, Akihiro U, Takumi M iPS progenitor cells and iPS cells WO2014167866A1. 2014.
  • Bamba M, Furuyama H, Sakamoto T, et al. Dihydropyrimidopyrimidine derivative. WO2010067886A1. 2010.
  • Sasai Y, Watanabe K Stem cell culture medium and method. WO2008035110A1. 2008.
  • Egli DM, Noggle SA, Eggan KC Method for producing pluripotent stem cells. WO2012071393A3. 2014.
  • Rana TM Promoting cellular reprogramming methods. WO2012166973A1. 2012.
  • Meng Z. Application of small molecule compound. CN103361305A. 2013.
  • Lin C, Ding S Small molecule cellular reprogramming to generate neuronal cells. WO2015041809A3. 2015.
  • Lum L, Roth M, Chen B, et al. Wnt protein signalling inhibitors. WO2009155001A3. 2010.
  • Chevalier B, Marson A, Young RA, et al. Wnt pathway stimulation in reprogramming somatic cells. WO2009032194A1. 2009.
  • Brivanlou A, Sato N, Meijer L Maintenance of Embryonic Stem Cells by the GSK-3 Inhibitor 6-Bromoindirubin-3ʹ-Oxime. US20090111177A1. 2009.
  • Perry JM, Li L, Grindley JC Methods and compositions for self-renewal of stem cells. WO2008133904A1. 2008.
  • Hochedlinger K, Stadtfeld M Tgf-beta receptor inhibitors to enhance direct reprogramming. US20140120621A1. 2014.
  • Li W, Zhou H, Ding S Generation and maintenance of stem cells. WO2010077955A1. 2011.
  • Lin T, Ding S Induction of pluripotent cells. US20120264218. 2015.
  • Kiwamu I, Kenichi M, Yuki H, et al. Method for producing a human corneal epithelial sheet. WO2014142038A1. 2014.
  • Kaether C, Krämer A Inhibitors of the notch signalling pathway and secretion for use in medicine. WO2013178821A1. 2013.
  • Grynspan F, Hasson A Methods for ex-vivo expanding stem/progenitor cells. WO2005007799A3. 2005.
  • Liu P, Wang W, Yang J Cells and methods for obtaining them. WO2011027180A1. 2011.
  • Zhu S, Ding S Reprogramming cells. WO2011123572A1. 2011.
  • Musick J Induced puripotent stem cells and related methods. WO2011062963A3. 2011.
  • You S, Moon JH, Kim JS, et al. Composition for reprogramming somatic cells to generate induced pluripotent stem cells, comprising oct4 in combination with bmi1 or its upstream regulator, and method for generating induced pluripotent stem cells using the same. US8772031A2. 2011.
  • Pei G, Yu J, Zhao J, et al. Organism lifetime based method for screening compounds capable of improving generation efficiency of induced pluripotent stem cells. CN102758000. 2015.
  • Deng H, Zhao Y, Hou P, et al. Compositions and methods for reprograming non- pluripotent cells into pluripotent stem cells. WO2015003643A1. 2015.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.